Compare OPTT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPTT | IFRX |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.0M | 71.1M |
| IPO Year | 2007 | 2017 |
| Metric | OPTT | IFRX |
|---|---|---|
| Price | $0.34 | $1.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $1.50 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 3.7M | 736.4K |
| Earning Date | 12-15-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,748,000.00 | $73,729.00 |
| Revenue This Year | $70.98 | N/A |
| Revenue Next Year | $106.21 | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.30 | $0.71 |
| 52 Week High | $1.75 | $2.77 |
| Indicator | OPTT | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.77 | 48.92 |
| Support Level | $0.30 | $1.07 |
| Resistance Level | $0.38 | $1.16 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 27.61 | 75.52 |
Ocean Power Technologies Inc provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets. It provides ocean data collection and reporting, marine power, offshore communications, and Maritime Domain Awareness System (MDAS) products, integrated solutions, and consulting services. The company offers its products and services to a wide range of customers, including those in government and offshore energy, oil and gas, construction, wind power, and other industries. The company has operations in North and South America, Europe, Asia and Australia.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.